Immuron’s Half-Year Revenue Hits A$4.18M as Loss Narrows 23%
Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.
- Half-year loss reduced by 23% to A$1.92 million
- Revenue up 4.8% to A$4.18 million driven by Travelan sales
- FDA approves IMM-529 IND for Phase 2 trial targeting C. difficile
- US Department of Defense funds new oral therapeutics development
- Raised A$7.15 million via At-the-Market equity facility
Financial Performance and Commercial Growth
Immuron Limited has reported a half-year loss of A$1.92 million for the six months ended 31 December 2025, improving from a loss of A$2.49 million in the prior corresponding period. This 23% reduction in losses comes alongside a 4.8% increase in revenue to A$4.18 million, driven primarily by record sales of its hyperimmune products, notably Travelan.
Sales of Travelan grew strongly in Australia and the United States, rising 11% and 17% respectively, although Canadian sales declined. The company’s operating profit from hyperimmune products was A$984,881, down slightly by 7% compared to the previous half-year, reflecting ongoing investment in marketing and research.
Regulatory Milestone: FDA IND Approval
A significant highlight for Immuron was the U.S. Food and Drug Administration’s approval of the Investigational New Drug (IND) application for IMM-529, enabling the company to commence a Phase 2 clinical trial targeting Clostridioides difficile infection (CDI). CDI is a major healthcare-associated infection with substantial morbidity and mortality, and IMM-529’s oral antibody therapy aims to prevent and treat recurrent infections.
Market assessments suggest IMM-529 could generate annual revenues of around US$400 million if successful, positioning it early in the treatment algorithm. The drug’s unique triple-target approach against C. difficile toxins and spores has shown promising preclinical results, potentially offering a safer adjunctive therapy to antibiotics.
Strategic Collaborations and Product Launches
Immuron also secured a new award from the U.S. Department of Defense to develop oral therapeutics targeting Campylobacter and Shigella infections, collaborating with military research institutes. This partnership underscores the company’s expanding footprint in infectious disease therapeutics beyond traveller’s diarrhoea.
In addition, Immuron launched PROIBS in Australia, a certified medical device for managing Irritable Bowel Syndrome symptoms. Early pharmacy orders and positive user feedback indicate potential for this product to complement the company’s digestive health portfolio.
Capital Position and Outlook
Immuron strengthened its balance sheet by raising approximately A$7.15 million through an At-the-Market equity facility, ending the period with nearly A$10 million in cash reserves. The company’s directors affirm that this cash position, combined with forecast sales and historical capital raising ability, supports operations for at least the next 12 months.
While the company continues to incur losses due to ongoing research and development, the commercial traction of its hyperimmune products and regulatory progress with IMM-529 provide a foundation for future growth. Investors will be watching closely for clinical trial outcomes and further commercial expansion.
Bottom Line?
Immuron’s blend of regulatory progress, commercial growth, and solid cash reserves sets the stage for a pivotal year ahead.
Questions in the middle?
- When will IMM-529 Phase 2 clinical trial data be available and what will it reveal about efficacy?
- How will Immuron address the decline in Canadian Travelan sales amid growth elsewhere?
- What are the timelines and commercial prospects for the new therapeutics funded by the US Department of Defense?
